Currently Viewing
4 Questions With a Surgeon: How to Improve Treatment of Glioblastoma
September 27, 2016 – Greg Kennelty
Column: Helping My Children Grow Strong Through My Cancer
September 26, 2016 – Wendy S. Harpham, M.D.
Seeking Less Toxic Treatments for Most Common Pediatric Brain Tumor
September 26, 2016 – Shannon Connelly
New AACR Report Highlights Impact of Cancer Research
September 22, 2016 – Allie Casey
Deeper Research Needed With Immunotherapy in Glioblastoma
September 22, 2016 – Laura Panjwani
Wolchok on Research, Perfecting Immunotherapy in Melanoma
September 21, 2016 – Laura Panjwani
Expert Highlights Progress, Looks Ahead in Kidney Cancer Care
September 21, 2016 – Gina Columbus
Study Evaluates Couple Communication During Advanced Cancer
September 20, 2016 – Allie Casey
Better Survival With Vaginal Brachytherapy in Endometrial Cancer
September 19, 2016 – Allie Strickler

4 Questions With a Surgeon: How to Improve Treatment of Glioblastoma

More advances, such as personalized approaches, still need to be made in treating glioblastoma, says Jennifer Moliterno Gunel, a brain surgeon from Yale.
BY Greg Kennelty
PUBLISHED September 27, 2016
While there have been significant surgical advancements to treat recurrent glioblastoma in recent years, Jennifer Moliterno Gunel, M.D., says that there is still progress that needs to be made, especially regarding more personalized care.
 
In an interview with CURE, Gunel, assistant professor of neurosurgery, Yale Medical Group, discusses re-radiation techniques for patients with recurrent glioblastoma, real time MRI technology that aids in the surgical process of resection, and the evolution of personalized medicine within the malignancy.

What are the current treatment options for patients with recurrent glioblastoma?

Typically for recurring glioblastoma, often times these patients are seen by neuro-oncologists. I'm a brain tumor surgeon, so they will frequently refer the patients back to me for re-resection, and that is often times an option. Meaning that we can go back and try to remove as much of the tumor as we can safely, which can provide symptomatic relief to the patient. It can also can lead us to really take a look at the tumor again, and have the pathologist look at the tumor again, to see if the mutational profile has changed.

Then of course there are additional options, which are usually chemotherapy or clinical trials, and there are various types of trials that we can offer at that point. Typically, radiation is used up front in the diagnosis of glioblastoma, and it's often a one-shot deal. Normally the patients get it for several weeks after the initial diagnosis. There are other studies now that are allowing for what we call ‘re-radiation.’
 
Frequently, glioblastoma up front would be treated with surgery, trying to remove as much of the tumor as possible safely, followed by radiation and chemotherapy. Recurring glioblastoma treatment is surgery, if amenable with keeping the patient's quality of life in line, followed by re-radiation and then some type of different chemotherapy. So not the standard chemotherapy that's given the first time around.
 

As a surgical oncologist, how have techniques evolved in recent years? Has new technology played a role in your job?

From the surgical standpoint, we try to, and there's evidence that shows that, the more tumor that we're able to remove, the better the results for patients and the better the outcomes for the patient are. It's still a very deadly disease of course, but it does make a difference having as much of a tumor removed as possible. Where surgery comes into play, it's trying to push the envelope to remove as much of the tumor as safely possible.
 
The way that we can do that with newer technology is with inter-operative MRI. That is helpful in that it gives real-time feedback to me about how much of the tumor I'm able to remove, and even being a brain tumor surgeon and seeing tumors day in and day out, the borders of the tumor can very much appear like brain, but still look like tumor on the MRI. Even when I think I've completed the removal of the tumor, I'll still get an MRI with the patient on the table and asleep, and that will show me if there's any tumor that remains that might just look like brain, but is really tumor. That allows me to be more aggressive with surgery.
 
The techniques that we use, especially at Yale, are different because we also use various neuromonitoring techniques and neuro-anasthesia. That way we're able to keep patients awake if we need to. For instance, if there's tumor that's near the speech areas, we might have the patient awake and talking to us during surgery, which again the end result is that we're able to remove more of the tumor and keeping them neurologically okay. That's important for getting through the radiation and chemotherapy aspects of glioblastoma treatments.

Are there any new treatment options on the horizon?

There's a lot of new ones throughout the spectrum, including taking other examples from other cancer types and trying to apply them to brain cancer. There's many trials that we're involved with at Yale, but one of the trials that I'm involved with has to do with injecting a retroviral replicating factor, so basically a virus, into the brain at the time of resection or removal of recurring glioblastoma. That virus encodes a specific enzyme, which basically converts a medication that's later given to the patient, which is a very well tolerated anti-fungal medication that people don't have many side effects from, and it converts it locally within the tumor cell into a chemotherapy drug.
 
It's been in trials for a little while and it shows promising results, and that's why we're really excited to open it at Yale. We opened it recently.
 

What are the biggest challenges in this space that you would like to see addressed?

I think it's a very heterogeneous disease, and so that's what makes it very difficult to really target effectively. I think that we probably need more sophisticated techniques with genetic testing of tumors, and we need to try to personalize medicine better, meaning that we find certain mutations that are in the tumor and then we can personalize or better target treatments for the disease. What I mean by heterogeneous is that these tumors have, compared to other tumor types, a lot more mutations. The problem with that is if you give everybody the same drug, it'll work for some but not for others. Moving forward and toward more personalized ways of tackling this is the way to go.
 


 
 
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Brain Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In